A detailed history of Israel Englander (Millennium Management LLC) transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Millennium Management LLC holds 399,510 shares of VNDA stock, worth $1.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
399,510
Previous 16,237 2360.49%
Holding current value
$1.85 Million
Previous $91,000 1958.24%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.61 - $6.34 $1.77 Million - $2.43 Million
383,273 Added 2360.49%
399,510 $1.87 Million
Q2 2024

Aug 14, 2024

SELL
$3.91 - $6.5 $1.63 Million - $2.71 Million
-416,565 Reduced 96.25%
16,237 $91,000
Q1 2024

May 15, 2024

SELL
$3.47 - $4.61 $1.96 Million - $2.61 Million
-565,490 Reduced 56.65%
432,802 $1.78 Million
Q4 2023

Feb 14, 2024

BUY
$3.38 - $4.58 $1.41 Million - $1.92 Million
418,518 Added 72.19%
998,292 $4.21 Million
Q2 2023

Aug 14, 2023

SELL
$5.9 - $6.95 $6.97 Million - $8.21 Million
-1,181,954 Reduced 67.09%
579,774 $3.82 Million
Q1 2023

May 15, 2023

SELL
$6.18 - $7.99 $136,065 - $175,915
-22,017 Reduced 1.23%
1,761,728 $12 Million
Q4 2022

Feb 14, 2023

BUY
$6.87 - $10.96 $11.2 Million - $17.9 Million
1,633,788 Added 1089.5%
1,783,745 $13.2 Million
Q3 2022

Nov 14, 2022

SELL
$9.44 - $11.76 $9.82 Million - $12.2 Million
-1,040,453 Reduced 87.4%
149,957 $1.48 Million
Q2 2022

Aug 15, 2022

BUY
$9.31 - $11.84 $3.32 Million - $4.22 Million
356,418 Added 42.74%
1,190,410 $13 Million
Q1 2022

May 16, 2022

BUY
$10.84 - $16.55 $4.27 Million - $6.53 Million
394,318 Added 89.68%
833,992 $9.43 Million
Q4 2021

Feb 14, 2022

SELL
$15.69 - $21.14 $2.62 Million - $3.53 Million
-167,070 Reduced 27.54%
439,674 $6.9 Million
Q3 2021

Nov 15, 2021

BUY
$15.35 - $21.27 $5.39 Million - $7.47 Million
351,137 Added 137.37%
606,744 $10.4 Million
Q2 2021

Aug 16, 2021

SELL
$15.71 - $21.51 $7.24 Million - $9.92 Million
-461,108 Reduced 64.34%
255,607 $5.5 Million
Q1 2021

May 17, 2021

BUY
$13.42 - $20.28 $979,727 - $1.48 Million
73,005 Added 11.34%
716,715 $10.8 Million
Q4 2020

Feb 16, 2021

BUY
$9.77 - $13.81 $4.65 Million - $6.57 Million
476,053 Added 283.94%
643,710 $8.46 Million
Q3 2020

Nov 16, 2020

BUY
$9.32 - $12.02 $1.56 Million - $2.02 Million
167,657 New
167,657 $1.62 Million
Q2 2020

Aug 14, 2020

SELL
$9.66 - $12.02 $2.71 Million - $3.37 Million
-280,178 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$7.5 - $16.8 $2 Million - $4.48 Million
266,565 Added 1958.16%
280,178 $2.9 Million
Q4 2019

Feb 14, 2020

SELL
$12.38 - $17.47 $5.55 Million - $7.83 Million
-448,362 Reduced 97.05%
13,613 $223,000
Q3 2019

Nov 14, 2019

SELL
$12.27 - $15.79 $740,494 - $952,926
-60,350 Reduced 11.55%
461,975 $6.14 Million
Q2 2019

Aug 14, 2019

SELL
$13.37 - $18.85 $1.81 Million - $2.56 Million
-135,697 Reduced 20.62%
522,325 $7.36 Million
Q1 2019

May 14, 2019

BUY
$17.59 - $31.05 $1.27 Million - $2.24 Million
72,158 Added 12.32%
658,022 $12.1 Million
Q4 2018

Feb 14, 2019

BUY
$18.97 - $31.47 $5.56 Million - $9.23 Million
293,273 Added 100.23%
585,864 $15.3 Million
Q3 2018

Nov 14, 2018

SELL
$18.25 - $23.0 $1.79 Million - $2.25 Million
-97,811 Reduced 25.05%
292,591 $6.72 Million
Q2 2018

Aug 14, 2018

SELL
$13.95 - $19.15 $8.45 Million - $11.6 Million
-605,873 Reduced 60.81%
390,402 $7.44 Million
Q1 2018

May 15, 2018

SELL
$14.05 - $20.2 $1.84 Million - $2.65 Million
-131,290 Reduced 11.64%
996,275 $16.8 Million
Q4 2017

Feb 14, 2018

SELL
$12.85 - $18.1 $4.02 Million - $5.67 Million
-313,196 Reduced 21.74%
1,127,565 $17.1 Million
Q3 2017

Nov 14, 2017

BUY
$15.4 - $18.85 $22.2 Million - $27.2 Million
1,440,761
1,440,761 $25.8 Million

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $262M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.